NZ628087A - Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same - Google Patents

Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Info

Publication number
NZ628087A
NZ628087A NZ628087A NZ62808710A NZ628087A NZ 628087 A NZ628087 A NZ 628087A NZ 628087 A NZ628087 A NZ 628087A NZ 62808710 A NZ62808710 A NZ 62808710A NZ 628087 A NZ628087 A NZ 628087A
Authority
NZ
New Zealand
Prior art keywords
pyrrolidine
methods
dione
preparing
same
Prior art date
Application number
NZ628087A
Other languages
English (en)
Inventor
Christopher A Lee
Martin P Redmon
John C Kane
David P Reed
Jian-Xie Chen
Neil R Barnes
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of NZ628087A publication Critical patent/NZ628087A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ628087A 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same NZ628087A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23
NZ600800A NZ600800A (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Publications (1)

Publication Number Publication Date
NZ628087A true NZ628087A (en) 2016-02-26

Family

ID=44188284

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ628087A NZ628087A (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
NZ600800A NZ600800A (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ600800A NZ600800A (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Country Status (19)

Country Link
US (3) US8552192B2 (enExample)
EP (2) EP2515904A4 (enExample)
JP (2) JP2013515737A (enExample)
KR (2) KR101669707B1 (enExample)
CN (2) CN104910159A (enExample)
AU (2) AU2010336533B9 (enExample)
BR (1) BR112012015656A2 (enExample)
CA (1) CA2785503A1 (enExample)
CO (1) CO6561823A2 (enExample)
HK (1) HK1215025A1 (enExample)
MX (1) MX2012007259A (enExample)
MY (2) MY169232A (enExample)
NZ (2) NZ628087A (enExample)
PH (2) PH12012501293A1 (enExample)
RU (1) RU2556205C2 (enExample)
SG (1) SG181927A1 (enExample)
TW (3) TWI506026B (enExample)
WO (1) WO2011079142A2 (enExample)
ZA (1) ZA201204759B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4171061B2 (ja) * 2005-02-09 2008-10-22 アーキュール,インコーポレーテッド マレイミド誘導体、医薬組成物、および癌の治療のためのその使用
AU2010336533B9 (en) * 2009-12-23 2015-10-08 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
MX2014000253A (es) 2011-07-07 2014-10-17 Arqule Inc Formulaciones de pirroloquinolinil-pirrolidin-2,5-diona y metodos para preparar y utilizar las mismas.
TW201350483A (zh) * 2012-04-23 2013-12-16 Arqule Inc 高純度吡咯並喹啉基-吡咯-2,5-二酮及吡咯並喹啉基-吡咯啶-2,5-二酮以及彼等之製備方法
EP3021849B1 (en) * 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
KR20250070131A (ko) * 2017-08-11 2025-05-20 액투에이트 테라퓨틱스 인크. 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의고체 형태
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4319740A4 (en) * 2021-04-07 2025-03-19 Crystalys Therapeutics, Inc. URAT1 INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
AU2072201A (en) * 1999-12-16 2001-06-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
IL161436A0 (en) * 2002-07-31 2004-09-27 Firmenich & Cie A process for the optical resolution of a precursor of sclareolide
CA2573508A1 (en) * 2004-09-10 2006-03-23 Wyeth Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyrano[3, 4-b]-indole derivatives
JP4171061B2 (ja) * 2005-02-09 2008-10-22 アーキュール,インコーポレーテッド マレイミド誘導体、医薬組成物、および癌の治療のためのその使用
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−2,5−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
EP2173748B1 (en) * 2007-06-22 2011-08-31 ArQule, Inc. Indolyl pyrrolidines for the treatment of cancer
AU2010336533B9 (en) * 2009-12-23 2015-10-08 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
TW201350483A (zh) * 2012-04-23 2013-12-16 Arqule Inc 高純度吡咯並喹啉基-吡咯-2,5-二酮及吡咯並喹啉基-吡咯啶-2,5-二酮以及彼等之製備方法

Also Published As

Publication number Publication date
CN104910159A (zh) 2015-09-16
WO2011079142A3 (en) 2011-11-24
MX2012007259A (es) 2015-05-15
CN102834097A (zh) 2012-12-19
AU2010336533A1 (en) 2012-07-12
US8552192B2 (en) 2013-10-08
AU2015243015A1 (en) 2015-11-05
CA2785503A1 (en) 2011-06-30
JP2013515737A (ja) 2013-05-09
PH12014500310A1 (en) 2015-09-28
HK1215025A1 (zh) 2016-08-12
JP2016041712A (ja) 2016-03-31
CN102834097B (zh) 2015-06-17
AU2010336533B9 (en) 2015-10-08
KR20160121602A (ko) 2016-10-19
NZ600800A (en) 2014-10-31
PH12012501293A1 (en) 2013-01-07
TWI506026B (zh) 2015-11-01
MY169232A (en) 2019-03-19
AU2015243015B2 (en) 2017-02-02
TWI557125B (zh) 2016-11-11
TW201542546A (zh) 2015-11-16
SG181927A1 (en) 2012-07-30
US20110160242A1 (en) 2011-06-30
EP3081567A3 (en) 2016-11-16
AU2010336533B2 (en) 2015-09-10
WO2011079142A2 (en) 2011-06-30
US8871933B2 (en) 2014-10-28
RU2012131344A (ru) 2014-01-27
KR101669707B1 (ko) 2016-10-27
BR112012015656A2 (pt) 2016-05-10
US20160024076A1 (en) 2016-01-28
KR20120113760A (ko) 2012-10-15
RU2556205C2 (ru) 2015-07-10
CO6561823A2 (es) 2012-11-15
EP2515904A4 (en) 2013-07-03
TW201643163A (zh) 2016-12-16
EP2515904A2 (en) 2012-10-31
US9499540B2 (en) 2016-11-22
MY156701A (en) 2016-03-15
ZA201204759B (en) 2014-03-26
EP3081567A2 (en) 2016-10-19
TW201141865A (en) 2011-12-01
US20140031551A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
NZ600800A (en) Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
WO2011082266A3 (en) Substituted heterocyclic compounds
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
MX2020002924A (es) Lactamas fusionadas de arilo y heteroarilo.
WO2009117676A3 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
MX2011008452A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
MX2012013274A (es) Novedosos derivados de la pirimidina.
NZ602578A (en) Polymorphic forms st-246 and methods of preparation
UA99787C2 (en) Lactams as beta secretase inhibitors
MX2013013465A (es) Polimorfo de rifaximina y proceso para la preparacion del mismo.
UA106887C2 (uk) Похідні спіроциклічних амідів
WO2010049449A3 (en) Novel salts of sunitinib
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
WO2009002807A3 (en) Indolyl pyrrolidines for the treatment of cancer
WO2008033935A3 (en) Vinorelbine derivatives
WO2012061342A3 (en) Substituted benzo-imidazo-pyrido-diazepine compounds
WO2010038948A3 (en) Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders
WO2011082271A3 (en) Substituted triazolo-pyrimidine compounds
WO2011029775A8 (en) [1,2,4]triazolo [1,5-c]pyrimidine derivatives as hsp90 modulators
WO2012088491A3 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
WO2011082269A3 (en) Substituted benzo-pyrimido-tetrazolo-diazepine compounds
HK1207313A1 (en) Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 DEC 2017 BY CULLENS PTY LTD

Effective date: 20160623

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2018 BY COMPUTER PACKAGES INC

Effective date: 20171201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2019 BY COMPUTER PACKAGES INC

Effective date: 20181201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2020 BY COMPUTER PACKAGES INC

Effective date: 20191203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2021 BY THOMSON REUTERS

Effective date: 20200926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2022 BY THOMSON REUTERS

Effective date: 20211102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2023 BY THOMSON REUTERS

Effective date: 20221102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2024 BY THOMSON REUTERS

Effective date: 20231101

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2025 BY THOMSON REUTERS

Effective date: 20241102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2026 BY THOMSON REUTERS

Effective date: 20251103